DOXYCYCLINE HYCLATE

Post-LOE

doxycycline hyclate

Pfizer

ANDAORALTABLET, DELAYED RELEASE

Approved

Jan 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXYCYCLINE HYCLATE (doxycycline hyclate) by Pfizer is [see microbiology (12. Approved for infections caused by the following microorganisms, bacteriological testing indicates appropriate susceptibility to the drug: respiratory tract infections caused by haemophilus influenzae, infections caused by the following gram-negative microorganisms and 6 more indications. First approved in 2022.

Drug data last refreshed 23h ago

Mechanism of Action

[see Microbiology (12.4)].

Indications (8)

infections caused by the following microorganisms bacteriological testing indicates appropriate susceptibility to the drug: Respiratory tract infections caused by Haemophilus influenzae

Worked on DOXYCYCLINE HYCLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01087476Phase 2Unknown

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Started May 2010

164 enrolled

Mucositis

NCT00688064Phase 3Completed

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Started Aug 2008

459 enrolled

Severe Acne Vulgaris